George Church, Ph.D.

  • Professor of Genetics at Harvard Medical School and a Director of the Center for Computational Genetics
  • Doctoral research included the first direct genomic sequencing method in 1984, which initiated his involvement in the Human Genome Project  at Biogen Inc. and University of California, San Francisco
  • Invented the broadly-applied concepts of molecular multiplexing and tags, homologous recombination methods and array DNA synthesizers
  • A leader in the gene editing space, with specific expertise in the optimization of CRISPR-based technology
  • Dr. Church holds a B.A. in Chemistry and Zoology from Duke University and a Ph.D. in Biochemistry and Molecular Biology from Harvard

Malcolm Brenner, M.D., Ph.D.

  • Founding Director of the Center for Cell and Gene Therapy of Baylor College of Medicine, The Methodist Hospital and Texas Children’s Hospital
  • Professor in the departments of Pediatrics and Medicine in the section of hematology-oncology at Baylor College of Medicine
  • Conducted one of the first human gene therapy studies, using retroviral vector to transduce bone marrow stem cells while working at St. Jude Children’s Research Hospital
  • Served as President of the International Society for Cellular Therapy, President of the American Society of Gene Therapy and Editor-in-Chief of the journal Molecular Therapy
  • Currently focused on increasing the activity and safety of T-lymphocytes directed to cancer cells by their native or synthetic receptors
  • Dr. Brenner holds a B.A., M.B. BChir and Ph.D. in immunology all from the University of Cambridge

Bruce Scharschmidt, M.D.

  • Former Senior Vice President and Chief Medical & Development Officer at Hyperion Therapeutics responisble for the development of RAVICTI®
  • Previously held senior positions at Novartis, Chiron, and the University of California, San Francisco
  • Author of over 200 research and review articles on liver biology and disease, Associate Editor of Gastroenterology, Editor-in-Chief of the Journal of Clinical Investigation, and President of the American Society for Clinical Investigation
  • Member of the Scientific Advisory Board for the Clinical and Translational Science Program at Northwestern/Feinberg School of Medicine and a member of the President’s Council Executive Committee of the Translational Team for the J David Gladstone Institute
  • Dr. Scharschmidt received his B.S. and M.D. from Northwestern University and is board-certified in internal medicine and gastroenterology

Don Siegel, M.D., Ph.D.

  • Professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania and Director of the Division of Transfusion Medicine and Therapeutic Pathology at the Hospital at the Univeristy of Pennsylvania
  • Medical Director of the blood bank and transfusion service, the apheresis, infusion and hematopoietic stem cell collection and processing units and the cellular engineering GMP facilities
  • Established an internationally-recognized cellular therapy program in the areas of oncology, infectious diseases and autoimmunity
  • Credited with a number of first-in-human clinical trials, including first use of lentiviral-transduced CAR-T or TCR T cells in cancer, first use of RNA electroporated T cells in cancer and first use of zinc finger nuclease genome edited T cells or lentiviral transduced TCR T cells for the treatment of HIV
  • Dr. Siegel holds a B.S. in Biophysics from Brown University, a Ph.D. in biophysics from Harvard and a M.D. from the University of Pennsylvania School of Medicine